NG-350A

AXP000038.1 · Oncolytic virus

Platform
adenovirus (Ad11p/Ad3 group B chimera, T-SIGn vector)
Originator
PsiOxus Therapeutics
Sponsor
Akamis Bio

Names

NameTypeSource
NG-350Apreferred name, codecurator, ncit

Virus

Role
Oncolytic
Family
Adenoviridae
Virus
human adenovirus 11 (NCBI Taxonomy 10541)
Strain
Ad11p/Ad3 group B chimera (T-SIGn)
Replication
conditionally replicating
Modifications
enadenotucirev backbone carrying a transgene cassette
Transgenes
anti-CD40 agonist antibody
Route
intravenous, intratumoral
Source
evidence

Cross-references

NCI Thesaurus
C159599

Approvals

No regulatory approval recorded.

Clinical trials (4)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT06459869NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal CancerActive not recruitingPhase 12025-04-072027-01-3033Locally Advanced Rectal Cancer (LARC)
NCT05165433Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY)CompletedPhase 12022-04-132025-08-2914Epithelial Tumor; Metastatic Cancer
NCT04787991Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic AdenocarcinomaCompletedPhase 12021-08-092024-11-1245Metastatic Pancreatic Adenocarcinoma
NCT03852511First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody)CompletedPhase 12019-02-192022-02-0428Epithelial Tumor; Metastatic Cancer

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 39414325First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironments.Journal for immunotherapy of cancer2024cited by trial NCT05165433
PMID 36897458A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies.Investigational new drugs2023cited by trial NCT03852511

Notes

Enadenotucirev (AXP000012) backbone armed with a full-length agonistic anti-CD40 antibody; separate construct, separate program. PsiOxus renamed itself Akamis Bio in January 2023.

How to cite

NG-350A (AXP000038.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000038.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.